Last verified: May 2026
The First-in-Nation Pharmacy Model
HB 324 / Georgia’s Hope Act of 2019 included a first-in-the-nation pilot allowing independent pharmacies to dispense low-THC oil under a Georgia Board of Pharmacy license. The framework went live in October 2024 after the Board approved implementing rules. The policy goal was to put ~90% of Georgians within a 30-minute drive of medical-cannabis access — meaningfully better geographic distribution than the 18 standalone dispensary locations could achieve alone.
The ~120 Partner Network
According to Botanical Sciences CEO Gary Long, quoted in Business of Cannabis in October 2024, the Georgia Board of Pharmacy signed up nearly 120 exclusive, independent pharmacy partners to dispense Botanical Sciences’ products statewide. The figure was confirmed in NORML and Atlanta Journal-Constitution reporting (cited by Marijuana Moment, November 2024).
Trulieve and the Class 2 producers (Fine Fettle, TheraTrue Georgia, Natures GA, Treevana Remedy) operate parallel pharmacy-dispensing networks — pharmacies sign agreements with one or more of the licensed Georgia producers and dispense their branded products.
Why CVS and Walgreens Declined
CVS and Walgreens, the two largest U.S. retail-pharmacy chains, are subject to federal frameworks (DEA registration for controlled-substance handling, Medicare and Medicaid participation, federal contracting in some lines) that make any Schedule I controlled-substance handling untenable. Both declined to participate in Georgia’s pharmacy-dispensing program from the start.
This is structurally consistent with the broader U.S. pharmacy industry posture — chain pharmacies have universally declined to dispense state-legal medical cannabis. The Georgia Board of Pharmacy framework therefore relies on independent pharmacies, which face less federal-program exposure but are typically smaller operations.
The November 27, 2024 DEA Warning Letters
⚠︐ On November 27, 2024, the U.S. Drug Enforcement Administration sent warning letters to participating pharmacies stating that dispensing Schedule I marijuana violated federal law. The letters reflected a long-standing federal-state conflict: cannabis remains Schedule I federally regardless of state-program status.
The GMCC discussed the warnings at a December 13, 2024 meeting. Some pharmacies suspended sales in response; others continued operating. The commission, chaired by Sid Johnson with Andrew Turnage as executive director, publicly committed to continuing patient access.
The Federal Schedule III Wildcard
Federal cannabis rescheduling — the proposed move from Schedule I to Schedule III — would substantially alter the pharmacy-dispensing landscape. Schedule III drugs are routinely dispensed by all U.S. retail pharmacies. If finalized, federal rescheduling would:
- Likely permit CVS and Walgreens to participate in Georgia’s program.
- Eliminate the DEA legal posture that produced the November 2024 warning letters.
- Open Georgia’s pharmacy-dispensing model as a template for other state programs.
The Schedule III move has been pending administrative finalization since 2024.
How Patients Use the Pharmacy Network
For an Amendment 98 patient, the pharmacy-dispensing network operates similarly to standalone dispensary purchases:
- Show your DPH Low-THC Oil card to the pharmacist.
- Present a physician-signed certification (refresh annually).
- Purchase up to the 20 fluid-ounce possession limit (per patient + caregivers collectively).
- Pay 4% state sales tax + local sales tax (typically 7–8% combined). No separate cannabis excise tax.
Finding a Participating Pharmacy
The Georgia Department of Community Health pharmacy directory lets users filter for "Low THC Pharmacy." The directory is updated continuously as new pharmacies enroll or suspend.
Practical Patient Notes
- The pharmacy-dispensing model puts most Georgians within a reasonable drive of access — particularly important given the ~18 standalone dispensary footprint can’t cover the state.
- Pharmacy hours typically exceed dispensary hours (some pharmacies are 24/7).
- Pharmacy staff are trained pharmacists familiar with drug interactions — a meaningful patient-safety advantage over standalone dispensary budtender consultations for patients on complex medication regimens.
- Federal cannabis rescheduling (Schedule III, pending) could substantially expand the pharmacy network if finalized.
- The DEA pushback creates ongoing uncertainty — check pharmacy-suspension status before assuming any specific pharmacy is currently dispensing.
For in-depth cannabis education, dosing guides, safety information, and research summaries, visit our partner site TryCannabis.org